Pharmaceuticalist Fined for Exorbitant Medicine Prices: ‘Abuse of Power
Hear is teh content you requested: PDF Summary of decision on abuse of dominant position by Leadiant – ACM.nl - When Leadiant sold CDCA-Leadiant from 2017, too, the revenues were a multiple of the costs thereof. The below figure shows the abovementioned price trend. Figure 1: Price trend of CDCA-based drugs of Leadiant, 2009-2019 … Read more
